COMMUNIQUÉS West-GlobeNewswire

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
22/04/2024
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse 1 Approval is based on results from the PHASE 3 CARTITUDE- [...]
RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call
22/04/2024
LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
22/04/2024
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting enables Evexta Bio to move forward in clinical development of rupitasertib in [...]
Nexstim Receives NBS 6 System Order from Clinic in Florida, US
22/04/2024
Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new [...]
Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
22/04/2024
EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute [...]
Transactions in Connection with Share Buy-back Program Genmab
22/04/2024
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
22/04/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22/04/2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli [...]
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
22/04/2024
Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024 Nicox Group cash of €9.1 million on [...]
Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023
22/04/2024
Communiqué de presse Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023 Chiffre d’affaires du Groupe de €4,4 millions (net 1 de €3,9 millions) pour le premier trimestre 2024 [...]
Samsung Bioepis Gains European Commission Approval For PYZCHIVA™, a Biosimilar to Stelara (Ustekinumab)
22/04/2024
PYZCHIVA becomes Samsung Bioepis’ fourth EC-approved immunology biosimilar Sandoz to commercialize PYZCHIVA in Europe INCHEON, Korea, April 22, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that the [...]
Mithra secures court protection measures to advance monetization process
22/04/2024
Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization. Approval of Judicial [...]
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
22/04/2024
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further [...]
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares
22/04/2024
Ipsen conclut un accord d'option pour les droits mondiaux exclusifs des candidats retenus dans le cadre de cette collaboration Une fois le candidat au développement validé, Ipsen sera responsable de la poursuite de son [...]
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
22/04/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva ® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to [...]
Ibogaine By David Dardashti' Investigates Correlation between Alcohol Addiction and Chemical Depression
22/04/2024
Ibogaine Clinic Aims to Create Sustainable Solutions to Treat Alcohol Addiction Miami, April 21, 2024 (GLOBE NEWSWIRE) -- The Ibogaine clinic by David Dardashti has announced its latest investigation into the [...]
Ibogaine By David Dardashti Offers New Treatment Procedure In Dedication Of Autism Awareness Month
22/04/2024
Ibogaine By David Dardashti Is Paving the Way For Autistic People With The Latest Treatment Procedure MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- To commemorate Autism Awareness Month, Ibogaine By David Dardashti is [...]
Ibogaine By David Dardashti Initiates Collaboration with Top Psychedelic Researchers
21/04/2024
Ibogaine By David Dardashti Seeks to Enhance Treatment Algorithms and Knowledge of Ibogaine MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leading ibogaine provider in the world, is proud to [...]
Quantum Electrodynamics and Ibogaine: Enhancing Work Performance
21/04/2024
Ibogaine By David Dardashti claims improved treatment efficacy due to electromagnetic waves MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leader in the field of ibogaine therapy, is [...]

Pages